Ha Kung Wong


Ha Kung Wong practices general intellectual property law with an emphasis on complex patent litigation in pharmaceuticals and chemistry. Cases Mr. Wong has litigated include those related to proton pump inhibitors, anti-epileptic drugs and other pharmaceuticals. 

Representative Experience

·   AstraZeneca against Andrx, Genpharm, Dr. Reddy and Schwartz Pharma on patents relating to omeprazole  and its formulations.

·   Bristol-Myers Squibb against The Regents of the University of Michigan and Repligen Corp. and ZymoGenetics on patents relating to synthetic fusion proteins for regulating the immune system.

·   UCB against Mylan, Dr. Reddy, Sandoz and Cobalt on patents relating to levetiracetam, a leading epilepsy medicine.

·   GlaxoSmithKline against Barr Pharmaceuticals on patents relating to dutasteride, a leading BPH drug.

{C}{C}{C}·   {C}{C}{C}UCB and Celltech against KV Pharmaceutical on patents relating to methylphenidate hydrochloride, an ADHD medicine.


Mr. Wong currently is the Chair of the Recruiting Committee and also serves as faculty for NITA (the National Institute of Trial Advocacy).


J.D. cum laude, Notre Dame Law School, 1999

B.S. Chemistry, High Distinction, B.S. Biochemistry, University of Illinois Urbana-Champaign, 1996

Bar Admissions

State of New York, 2000; U.S. District Courts for the Southern and Eastern Districts of New York, 2001

Professional Activities

American Bar Association; New York Bar Association; New York Patent Law Association; American Chemical Society; New York Intellectual Property Law Association


·   While in law school, Mr. Wong served as Managing Editor for the Journal of Legislation and published, "The Extra in Extradition: Washington v. Pang's Impact on Extraditee Standing and Implicit Waiver," 24 J.Legis 111 (1998).

·   Published, Wong, H. & Lau, D., "Combine and conquer: handling biotech combination inventions in the wake of KSR," Nat. Biotechnol. 27, 446-448 (2009).

·   Published, Wong, H. & Saha, S., "Obvious to Try? The Slippery Slope of Biotechnology," Bloomberg Law Reports, Vol. 4, No. 19, 8-11 (May 10, 2010).

·   Published, Wong, H. & Gupta, V., "Recent legislation impacts development of biologics," Financier Worldwide, (November 2010).

·   Published, Wong, H. & McMahon, D., "Preparing for uncertainties in biosimilars litigation," Financier Worldwide, pg. 37-8 (January 2011).

·    Published, Wong, H., Pierson, R.W., Wang, S., "Trade Secret Law Reform: Could an Amended Economic Espionage Act Overcome Inconsistencies in the Current State Law System?" Bloomberg Law Reports, Intellectual Property, Vol. 6, No. 3, 21-6 (January 17, 2012).

·   Published, Wong, H & Pierson, R.W., "Conducting an IP Audit When Laws Change", New York Law Journal (May 9, 2012)

Practice Areas

  • Intellectual Property

3 Courses by Ha Kung Wong